Clinical Trials
33 trialsComparison of Two Schedules of Zoledronic Acid in Treating Patients With Breast Cancer That Has Spread to the Bone
University of Leeds
MOSCAR
Centre Leon Berard
BLAZE
First Affiliated Hospital, Sun Yat-Sen University
Zolendronate for the Prevention of Bone Loss in Men w/ Prostate CA on Long-Term Androgen Deprivation
Northwestern University
Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid
City of Hope Medical Center
Zoledronic Acid With Intermittent Hormonal Therapy in Patients With Prostate Cancer
Stanford University
Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer
University of Wisconsin, Madison
Overcoming Chemotherapy Resistance In Refractory Multiple Myeloma With Simvastatin and Zoledronic Acid
University of Louisville
Zoledronic Acid Administration to Metastatic Breast Cancer Patients With Non-symptomatic Bone Lesions
Spanish Breast Cancer Research Group
Pre-operative Zoledronate in Triple Negative Breast Cancer
Mario Negri Institute for Pharmacological Research
Using TRAP to Evaluate the Effect of Zometa on Bone Metastasis Due to Lung Cancer
University of Louisville
Zoledronate in Treating Patients With Cervical Intraepithelial Neoplasia 2/3 or 3
University of California, San Francisco
A Study to Assess the Efficacy of Intravenous/Oral Bondronat (Ibandronate) in Patients With Metastatic Bone Disease Experiencing Moderate to Severe Pain
Hoffmann-La Roche
A Study to Assess the Efficacy of Intravenous Bondronat (Ibandronate) in Patients With Malignant and Painful Bone Disease
Hoffmann-La Roche
COMPARE
Hoffmann-La Roche
HR-GCT
Leiden University Medical Center
Study of Zoledronic Acid Versus Observation on Bone Mineral Density and Incidence of Micrometastasis in Women Undergoing Pelvic Radiation for Cervical Cancer
Washington University School of Medicine
Low-Dose/Metronomic(LDM)Chemotherapy for Metastatic Breast Cancer
HaEmek Medical Center, Israel
Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma
University of Alabama at Birmingham
A Study of Zoledronic Acid in the Prevention of Cancer Therapy-induced Bone Loss
Novartis
Perioperative Treatment With Zoledronic Acid in Patients With Resectable Pancreas Cancer
Washington University School of Medicine
Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD)
H. Lee Moffitt Cancer Center and Research Institute
Zometa
Nantes University Hospital
Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy to Prevent Bone Metastases in Patients With Recurrent Prostate Cancer That Has No Symptoms
Novartis
Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders
Roswell Park Cancer Institute
ZAP
Rochester General Hospital
ZOMETA® (Zoledronic Acid) for Prevention of Bone Metastases
Central European Cooperative Oncology Group
Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I
Novartis
Zoledronic Acid in the Management of Patients With Asymptomatic/Early Stage Multiple Myeloma
Hoosier Cancer Research Network
Adjuvant Docetaxel-Zoledronic Acid in High-risk Early Prostate Cancer Following Prostatectomy.
Novartis
MRD-1
Novartis
Safety/Efficacy of Intravenous Zoledronic Acid When Added to Standard Therapies in Patients With Breast Cancer and Metastatic Bone Lesions
Novartis
Maintaining Bone Strength in Men With Prostate Cancer
Novartis